Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Pierre Van Damme, Geert Leroux-Roels, P. Suryakiran, Nicolas Folschweiller & Olivier Van Der Meeren. (2017) Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Human Vaccines & Immunotherapeutics 13:5, pages 972-980.
Read now
Read now
Anke L. Stuurman, Cinzia Marano, Eveline M. Bunge, Laurence De Moerlooze & Daniel Shouval. (2017) Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review. Human Vaccines & Immunotherapeutics 13:3, pages 724-736.
Read now
Read now
Yueyuan Zhao, Hui Jin, Xuefeng Zhang, Bei Wang & Pei Liu. (2016) Viral hepatitis vaccination during pregnancy. Human Vaccines & Immunotherapeutics 12:4, pages 894-902.
Read now
Read now
Olivier Van Der Meeren, Priya Crasta & Marc de Ridder. (2015) A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults. Human Vaccines & Immunotherapeutics 11:7, pages 1729-1734.
Read now
Read now
Xue-en Liu, Fuerhati Wushouer, Aili Gou, Mahemuti Kuerban, Xinlan Li, Yubo Sun, Jiamin Zhang, Yan Liu, Jie Li & Hui Zhuang. (2013) Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines. Human Vaccines & Immunotherapeutics 9:7, pages 1460-1465.
Read now
Read now
Jun-Yu Wu, Yan Liu, Jiang-Ting Chen, Ming Xia & Xiao-Mei Zhang. (2012) Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®. Human Vaccines & Immunotherapeutics 8:12, pages 1836-1844.
Read now
Read now
Koen Van Herck, Priya Diana Crasta, Marc Messier, Karin Hardt & Pierre Van Damme. (2012) Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Human Vaccines & Immunotherapeutics 8:3, pages 323-327.
Read now
Read now
Hans Dieter Nothdurft. (2008) Hepatitis A vaccines. Expert Review of Vaccines 7:5, pages 535-545.
Read now
Read now
Articles from other publishers (29)
Kamran Bagheri Lankarani, Behnam Honarvar, Ali Davoodi, Naeimehossadat Asmarian, Mohammad Reza Serati, Mohsen Ali Akbarpour, Erfan Sadeghi, Touba Narimani Moghadam & Hossein Molavi Vardanjani. (2023) Hepatitis A Chronic Immunity in Iran: A Geographic Information System-Based Study. Hepatitis Monthly In Press:In Press.
Crossref
Crossref
Adam T Biggs & Lanny F Littlejohn. (2023) Describing mRNA Vaccine Technology for a Military Audience. Military Medicine 188:3-4, pages 547-554.
Crossref
Crossref
Mark K. Weng, Noele P. Nelson & Monique A. Foster. 2023. Principles and Practice of Pediatric Infectious Diseases. Principles and Practice of Pediatric Infectious Diseases
1237
1243.e3
.
Tobias Laue, Johanna Ohlendorf, Christoph Leiskau & Ulrich Baumann. (2022) Hepatitis A Immunity and Paediatric Liver Transplantation—A Single-Centre Analysis. Children 9:12, pages 1953.
Crossref
Crossref
Karen K. Kyuregyan, Maria A. Lopatukhina, Fedor A. Asadi Mobarkhan, Vera S. Kichatova, Ilya A. Potemkin, Olga V. Isaeva, Anastasia A. Karlsen, Elena Yu. Malinnikova, Alla N. Kaira, Tatyana V. Kozhanova, Victor A. Manuylov, Elena P. Mazunina, Evgeniia N. Bykonia, Denis A. Kleymenov, Margarita E. Ignateva, Olga E. Trotsenko, Anna V. Kuznetsova, Anna A. Saryglar, Natalia D. Oorzhak, Victor V. Romanenko & Mikhail I. Mikhailov. (2022) Dynamic Changes in Hepatitis A Immunity in Regions with Different Vaccination Strategies and Different Vaccination Coverage. Vaccines 10:9, pages 1423.
Crossref
Crossref
Young Hun Chung, Derek Church, Edward C. Koellhoffer, Elizabeth Osota, Sourabh Shukla, Edward P. Rybicki, Jonathan K. Pokorski & Nicole F. Steinmetz. (2021) Integrating plant molecular farming and materials research for next-generation vaccines. Nature Reviews Materials 7:5, pages 372-388.
Crossref
Crossref
M. I. Mikhailov & K. K. Kyuregyan. (2021) Contemporary strategy to control viral hepatitis A in the Russian Federation. Journal of microbiology, epidemiology and immunobiology 98:2, pages 190-197.
Crossref
Crossref
Halle Lutz, Kristen D. Popowski, Phuong-Uyen C. Dinh & Ke Cheng. (2021) Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. Advanced NanoBiomed Research 1:3.
Crossref
Crossref
Patricia Juliao, Ivonne Abadia, Sarah Welby, Stéphanie Wéry, Digna Wong, Tirza De Léon, Rodrigo DeAntonio, Laura Naranjo, Adrienne Guignard & Cinzia Marano. (2021) Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama. Vaccine 39:1, pages 26-34.
Crossref
Crossref
Noele P. Nelson, Mark K. Weng, Megan G. Hofmeister, Kelly L. Moore, Mona Doshani, Saleem Kamili, Alaya Koneru, Penina Haber, Liesl Hagan, José R. Romero, Sarah Schillie & Aaron M. Harris. (2020) Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR. Recommendations and Reports 69:5, pages 1-38.
Crossref
Crossref
M. P. Pogorily, М. I. Mizyuk, O. S. Malyshevska, М. YE. Ionda, I. T. Tokar & YA. O. Yeremchuk. (2018) The Features Of The Epidemic Process Of Hepatitis A And Its Connection With Accumulation Of Household Polymeric Waste In The Environment. Naukovì dopovìdì Nacìonalʹnogo unìversitetu bìoresursiv ì prirodokoristuvannâ Ukraïni:2(72).
Crossref
Crossref
F. Ma, J. Yang, G. Kang, Q. Sun, P. Lu, Y. Zhao, Z. Wang, J. Luo & Z. Wang. (2016) Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study. Clinical Microbiology and Infection 22:9, pages 811.e9-811.e15.
Crossref
Crossref
Nada Melhem, Khalil Kreidieh & Sami Ramia. (2016) The Syrian refugees crisis brings challenges to the health authorities in Europe: hepatitis A virus is a case in point. European Journal of Epidemiology 31:7, pages 711-714.
Crossref
Crossref
Heidi Theeten, Koen Van Herck, Olivier Van Der Meeren, Priya Crasta, Pierre Van Damme & Niel Hens. (2015) Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 33:42, pages 5723-5727.
Crossref
Crossref
Philipp Uhl, Gert Fricker, Uwe Haberkorn & Walter Mier. (2014) Current Status in the Therapy of Liver Diseases. International Journal of Molecular Sciences 15:5, pages 7500-7512.
Crossref
Crossref
Wouter van den Bijllaardt, Helen M. Siers, Caroline Timmerman‐Kok, Franciscus G. Pessers, Gerard Natrop, Joep F. van Baars, Nynke Nutma, Douwe van der Werf & Elizabeth H. Gisolf. (2013) Seroprotection After Hepatitis A Vaccination in Patients With Drug‐Induced Immunosuppression. Journal of Travel Medicine 20:5, pages 278-282.
Crossref
Crossref
Koen Van Herck, Jeanne‐Marie Jacquet & Pierre Van Damme. (2011) Antibody persistence and immune memory in healthy adults following vaccination with a two‐dose inactivated hepatitis A vaccine: Long‐term follow‐up at 15 years. Journal of Medical Virology 83:11, pages 1885-1891.
Crossref
Crossref
Luciano Mariani & Aldo Venuti. (2010) HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. Journal of Translational Medicine 8:1.
Crossref
Crossref
Guo-Lin Bian, Rui Ma, Hong-Jun Dong, Hong-Xia Ni, Feng-Jiao Hu, Yao-rong Chen, Jia-Qun Chen, Shao-Ying Zhou, Yong-Xin Lin & Guo-Zhang Xu. (2010) Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 28:30, pages 4798-4801.
Crossref
Crossref
L. Salleras. (2009) Vacunación universal frente a la hepatitis A. Vacunas 10:1, pages 1-3.
Crossref
Crossref
Mary Beth Koslap-Petraco, Mitchell Shub & Richard Judelsohn. (2008) Hepatitis A: Disease Burden and Current Childhood Vaccination Strategies in the United States. Journal of Pediatric Health Care 22:1, pages 3-11.
Crossref
Crossref
Pamela Rendi‐Wagner, Maria Korinek, Andrea Mikolasek, Andreas Vécsei & Herwig Kollaritsch. (2007) Epidemiology of Travel‐Associated and Autochthonous Hepatitis A in Austrian Children, 1998 to 2005. Journal of Travel Medicine 14:4, pages 248-253.
Crossref
Crossref
Mario Rizzetto & Fabien Zoulim. 2007. Textbook of Hepatology. Textbook of Hepatology
819
956
.
Jorma Paavonen, David Jenkins, F Xavier Bosch, Paulo Naud, Jorge Salmerón, Cosette M Wheeler, Song-Nan Chow, Dan L Apter, Henry C Kitchener, Xavier Castellsague, Newton S de Carvalho, S Rachel Skinner, Diane M Harper, James A Hedrick, Unnop Jaisamrarn, Genara AM Limson, Marc Dionne, Wim Quint, Bart Spiessens, Pascal Peeters, Frank Struyf, Susan L Wieting, Matti O Lehtinen & Gary Dubin. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet 369:9580, pages 2161-2170.
Crossref
Crossref
Ahmet Soysal, Ibrahim Gokçe, Tamer Pehlivan & Mustafa Bakir. (2007) Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey. European Journal of Pediatrics 166:6, pages 533-539.
Crossref
Crossref
Pierre Van Damme & Koen Van Herck. (2007) A review of the long-term protection after hepatitis A and B vaccination. Travel Medicine and Infectious Disease 5:2, pages 79-84.
Crossref
Crossref
I. Kohl, V. Němeček, M. Summerová, R. Chlíbek, K. Nad’ová & O. Mináriková. (2006) Long-term protective effect of post-exposure Havrix TM administration during viral hepatitis Type A outbreaks. European Journal of Epidemiology 21:12, pages 893-899.
Crossref
Crossref
Xuan-Yi Wang, Zhi-Yi Xu, Jing-Chen Ma, Lorenz von Seidlein, Yong Zhang, Zhi-Yong Hao, Oak Pil Han, Ying-Lin Zhang, Mei-Ying Tian, Pei-Ying Ouyang, Zhi-Yong Zhang, Chang-Quan Han, Zhan-Chun Xing & Ji-Chao Chen. (2007) Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: Results from 8-year follow-up. Vaccine 25:3, pages 446-449.
Crossref
Crossref
Jane N Zuckerman. (2006) Vaccination against hepatitis A and B: developments, deployment and delusions. Current Opinion in Infectious Diseases 19:5, pages 456-459.
Crossref
Crossref